2,000
Participants
Start Date
December 3, 2020
Primary Completion Date
July 30, 2025
Study Completion Date
December 31, 2025
lerodalcibep
PCSK9 inhibitor
Carbohydrate and Lipid Metabolism Research Unit, Johannesburg
Division of Lipidology, Department of Medicine University of Cape Town, Cape Town
Department of Medicine, Hadassah University Hospital, Jerusalem
Ege University Medical School, Izmir
Sterling Research Group, Cincinnati
The Lindner Research Center, Cincinnati
Metabolic & Atherosclerosis Research Center (MARC), Cincinnati
Rabin Medical Center, Beilinson Hospital,, Petah Tikva
NorthShore University Health System, Evanston
G.B. Pant Institute of Postgraduate Medical Education & Research, New Delhi
Lipid Clinic, Oslo University Hospital, Oslo
Afyonkarahisar Health Sciences University, Afyonkarahisar
Lead Sponsor
Collaborators (1)
Medpace, Inc.
INDUSTRY
LIB Therapeutics LLC
INDUSTRY